Healthcare / Health Information ServicesNasdaqGS
$0.99
+0.06 (+5.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $38.2M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$104M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-49.4%
↓Gross Margin
75.9%
↑Debt/Equity
0.61
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+15.3%
FCF CAGR
+11.2%
FCF margin
15.3%
FCF / Net income
-0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $241.5M · net income $-138.9M · FCF $37.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $241.5M | $241.5M | $252.2M | $251.4M | $222.7M | $166.2M | $118.3M |
| Net Income | $-138.9M | $-138.9M | $-413.1M | $-202.4M | $-7.2M | $-17.8M | $0.00 |
| EBITDA | $-141.9M | $-141.9M | $-567.2M | $-241.2M | $26.2M | $-25.6M | $-14.7M |
| EPS | -1.30 | -1.30 | -3.54 | -1.79 | -0.06 | -0.19 | — |
| Gross Margin | 75.9% | 75.9% | 78.3% | 81.1% | 80.9% | 75.5% | 74.2% |
| Operating Margin | -8.5% | -8.5% | -3.9% | -12.3% | -16.2% | -16.4% | -13.4% |
| Net Margin | -57.5% | -57.5% | -163.8% | -80.5% | -3.2% | -10.7% | 0.0% |
| Balance Sheet | |||||||
| Debt/Equity | 0.61 | 0.61 | 0.57 | 0.31 | 0.29 | — | — |
| Current Ratio | 1.75 | 1.75 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $37.1M | $37.1M | $45.9M | $38.2M | $27.3M | $18.5M | $21.8M |
| Returns | |||||||
| ROE | -49.4% | -49.4% | -93.0% | -23.5% | -0.8% | — | — |
| Valuation | |||||||
| EV/EBITDA | — | — | — | — | 45.05 | — | — |
| P/B | 0.37 | 0.37 | 1.14 | 1.18 | 1.11 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -4.2% | -4.2% | 0.3% | 12.9% | — | 40.4% | — |
| EPS Growth | 63.3% | 63.3% | -97.8% | -2883.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-70.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.54 → -1.30
Residual
-70.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.